Skip to main content
PMC home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1999 Oct;81(3):469–475. doi: 10.1038/sj.bjc.6690717

The nm23-H1 gene as a predictor of sensitivity to chemotherapeutic agents in oesophageal squamous cell carcinoma

N Iizuka 1,2, K Hirose 3, T Noma 4, S Hazama 2, A Tangoku 2, H Hayashi 2, T Abe 2, K Yamamoto 2, M Oka 2
PMCID: PMC2362931  PMID: 10507772

Abstract

Recently, nm23-H1, an anti-metastasis gene, has been reported to correlate with sensitivity to chemotherapeutic agents including cisplatin in human breast and ovarian carcinoma cells. The aim of this study was to evaluate a role for nm23-H1 in responsiveness to cisplatin-based chemotherapy in patients with oesophageal squamous cell carcinoma (OSCC). The expression of nm23-H1 protein was examined immunohistochemically in 32 eligible patients with OSCC who underwent adjuvant chemotherapy with cisplatin, etoposide, and 5-fluorouracil after tumour resection. Fifteen (46.9%) of 32 patients were positive for nm23-H1 staining and 17 (53.1%) were negative. Both disease-free survival and overall survival rates of nm23-H1-negative patients were significantly shorter than in nm23-H1-positive patients (P < 0.01 for both). There was no significant difference in clinicopathologic characteristics between nm23-H1-positive and nm23-H1-negative groups. Multivariate analysis also showed that nm23-H1 expression was the most significant factor for overall survival of OSCC patients included in this study (P = 0.0007). To further study the role of nm23-H1, a human OSCC cell line (YES-2) was transfected with a plasmid containing a fragment of the nm23-H1 cDNA in an antisense orientation. Reduced expression of nm23-H1 protein in the antisense-transfected (AS) clones was found by Western blot analysis as compared to wild-type YES-2 and YES-2/Neo (clone transfected with the neomycin resistance gene alone). MTT (3-(4,5-dimethyl-2-thiazol)-2,5-diphenyl-2H tetrazolium bromide) assay showed that reduced expression of the nm23-H1 protein in AS clones was consistent with the degree of increased resistance to cisplatin but not etoposide or 5-fluorouracil. These data support the conclusion that reduced expression of nm23-H1 may be associated with resistance to cisplatin, suggesting the value of nm23-H1 expression as a prognostic marker for OSCC patients who are to undergo cisplatin-based chemotherapy. © 1999 Cancer Research Campaign

Keywords: nm23, cisplatin, chemotherapy, prognosis, oesophageal squamous cell carcinoma

Full Text

The Full Text of this article is available as a PDF (228.0 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Andrews P. A., Albright K. D. Mitochondrial defects in cis-diamminedichloroplatinum(II)-resistant human ovarian carcinoma cells. Cancer Res. 1992 Apr 1;52(7):1895–1901. [PubMed] [Google Scholar]
  2. Berridge M. V., Tan A. S. Characterization of the cellular reduction of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT): subcellular localization, substrate dependence, and involvement of mitochondrial electron transport in MTT reduction. Arch Biochem Biophys. 1993 Jun;303(2):474–482. doi: 10.1006/abbi.1993.1311. [DOI] [PubMed] [Google Scholar]
  3. Bosset J. F., Gignoux M., Triboulet J. P., Tiret E., Mantion G., Elias D., Lozach P., Ollier J. C., Pavy J. J., Mercier M. Chemoradiotherapy followed by surgery compared with surgery alone in squamous-cell cancer of the esophagus. N Engl J Med. 1997 Jul 17;337(3):161–167. doi: 10.1056/NEJM199707173370304. [DOI] [PubMed] [Google Scholar]
  4. Caligo M. A., Cipollini G., Fiore L., Calvo S., Basolo F., Collecchi P., Ciardiello F., Pepe S., Petrini M., Bevilacqua G. NM23 gene expression correlates with cell growth rate and S-phase. Int J Cancer. 1995 Mar 16;60(6):837–842. doi: 10.1002/ijc.2910600619. [DOI] [PubMed] [Google Scholar]
  5. De Giovanni C., Landuzzi L., Frabetti F., Nicoletti G., Griffoni C., Rossi I., Mazzotti M., Scotto L., Nanni P., Lollini P. L. Antisense epidermal growth factor receptor transfection impairs the proliferative ability of human rhabdomyosarcoma cells. Cancer Res. 1996 Sep 1;56(17):3898–3901. [PubMed] [Google Scholar]
  6. Easty D. J., Maung K., Lascu I., Véron M., Fallowfield M. E., Hart I. R., Bennett D. C. Expression of NM23 in human melanoma progression and metastasis. Br J Cancer. 1996 Jul;74(1):109–114. doi: 10.1038/bjc.1996.323. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Ferguson A. W., Flatow U., MacDonald N. J., Larminat F., Bohr V. A., Steeg P. S. Increased sensitivity to cisplatin by nm23-transfected tumor cell lines. Cancer Res. 1996 Jul 1;56(13):2931–2935. [PubMed] [Google Scholar]
  8. Flørenes V. A., Aamdal S., Myklebost O., Maelandsmo G. M., Bruland O. S., Fodstad O. Levels of nm23 messenger RNA in metastatic malignant melanomas: inverse correlation to disease progression. Cancer Res. 1992 Nov 1;52(21):6088–6091. [PubMed] [Google Scholar]
  9. Freije J. M., Lawrence J. A., Hollingshead M. G., De la Rosa A., Narayanan V., Grever M., Sausville E. A., Paull K., Steeg P. S. Identification of compounds with preferential inhibitory activity against low-Nm23-expressing human breast carcinoma and melanoma cell lines. Nat Med. 1997 Apr;3(4):395–401. doi: 10.1038/nm0497-395. [DOI] [PubMed] [Google Scholar]
  10. Gauthier T., Denis-Pouxviel C., Murat J. C. Respiration of mitochondria isolated from differentiated and undifferentiated HT29 colon cancer cells in the presence of various substrates and ADP generating systems. Int J Biochem. 1990;22(4):411–417. doi: 10.1016/0020-711x(90)90145-s. [DOI] [PubMed] [Google Scholar]
  11. Higashiyama M., Doi O., Yokouchi H., Kodama K., Nakamori S., Tateishi R., Kimura N. Immunohistochemical analysis of nm23 gene product/NDP kinase expression in pulmonary adenocarcinoma: lack of prognostic value. Br J Cancer. 1992 Sep;66(3):533–536. doi: 10.1038/bjc.1992.308. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Hishikawa Y., Abe S., Kinugasa S., Yoshimura H., Monden N., Igarashi M., Tachibana M., Nagasue N. Overexpression of metallothionein correlates with chemoresistance to cisplatin and prognosis in esophageal cancer. Oncology. 1997 Jul-Aug;54(4):342–347. doi: 10.1159/000227714. [DOI] [PubMed] [Google Scholar]
  13. Iizuka N., Oka M., Noma T., Nakazawa A., Hirose K., Suzuki T. NM23-H1 and NM23-H2 messenger RNA abundance in human hepatocellular carcinoma. Cancer Res. 1995 Feb 1;55(3):652–657. [PubMed] [Google Scholar]
  14. Jiang W. G., Hiscox S., Bryce R. P., Horrobin D. F., Mansel R. E. The effects of n-6 polyunsaturated fatty acids on the expression of nm-23 in human cancer cells. Br J Cancer. 1998 Mar;77(5):731–738. doi: 10.1038/bjc.1998.120. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Kok T. C., Van der Gaast A., Dees J., Eykenboom W. M., Van Overhagen H., Stoter G., Tilanus H. W., Splinter T. A. Cisplatin and etoposide in oesophageal cancer: a phase II study. Rotterdam Oesophageal Tumour Study Group. Br J Cancer. 1996 Sep;74(6):980–984. doi: 10.1038/bjc.1996.469. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Lindmark G. NM-23 H1 immunohistochemistry is not useful as predictor of metastatic potential of colorectal cancer. Br J Cancer. 1996 Nov;74(9):1413–1418. doi: 10.1038/bjc.1996.557. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. McLeod H. L., Sludden J., Murray G. I., Keenan R. A., Davidson A. I., Park K., Koruth M., Cassidy J. Characterization of dihydropyrimidine dehydrogenase in human colorectal tumours. Br J Cancer. 1998;77(3):461–465. doi: 10.1038/bjc.1998.73. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Nguyen H. N., Sevin B. U., Averette H. E., Perras J., Ramos R., Donato D., Ochiai K., Penalver M. Cell cycle perturbations of platinum derivatives on two ovarian cancer cell lines. Cancer Invest. 1993;11(3):264–275. doi: 10.3109/07357909309024851. [DOI] [PubMed] [Google Scholar]
  19. Nita M. E., Nagawa H., Tominaga O., Tsuno N., Fujii S., Sasaki S., Fu C. G., Takenoue T., Tsuruo T., Muto T. 5-Fluorouracil induces apoptosis in human colon cancer cell lines with modulation of Bcl-2 family proteins. Br J Cancer. 1998 Oct;78(8):986–992. doi: 10.1038/bjc.1998.617. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Oka M., Iizuka N., Yamamoto K., Gondo T., Abe T., Hazama S., Akitomi Y., Koishihara Y., Ohsugi Y., Ooba Y. The influence of interleukin-6 on the growth of human esophageal cancer cell lines. J Interferon Cytokine Res. 1996 Dec;16(12):1001–1006. doi: 10.1089/jir.1996.16.1001. [DOI] [PubMed] [Google Scholar]
  21. Olivero O. A., Semino C., Kassim A., Lopez-Larraza D. M., Poirier M. C. Preferential binding of cisplatin to mitochondrial DNA of Chinese hamster ovary cells. Mutat Res. 1995 Apr;346(4):221–230. doi: 10.1016/0165-7992(95)90039-x. [DOI] [PubMed] [Google Scholar]
  22. Patel D. D., Bhatavdekar J. M., Chikhlikar P. R., Patel Y. V., Shah N. G., Ghosh N., Suthar T. P., Balar D. B. Clinical significance of p53, nm23, and bcl-2 in T3-4N1M0 oesophageal carcinoma: an immunohistochemical approach. J Surg Oncol. 1997 Jun;65(2):111–116. doi: 10.1002/(sici)1096-9098(199706)65:2<111::aid-jso7>3.0.co;2-a. [DOI] [PubMed] [Google Scholar]
  23. Roder J. D., Busch R., Stein H. J., Fink U., Siewert J. R. Ratio of invaded to removed lymph nodes as a predictor of survival in squamous cell carcinoma of the oesophagus. Br J Surg. 1994 Mar;81(3):410–413. doi: 10.1002/bjs.1800810330. [DOI] [PubMed] [Google Scholar]
  24. Rusch V., Klimstra D., Venkatraman E., Oliver J., Martini N., Gralla R., Kris M., Dmitrovsky E. Aberrant p53 expression predicts clinical resistance to cisplatin-based chemotherapy in locally advanced non-small cell lung cancer. Cancer Res. 1995 Nov 1;55(21):5038–5042. [PubMed] [Google Scholar]
  25. Scambia G., Ferrandina G., Marone M., Benedetti Panici P., Giannitelli C., Piantelli M., Leone A., Mancuso S. nm23 in ovarian cancer: correlation with clinical outcome and other clinicopathologic and biochemical prognostic parameters. J Clin Oncol. 1996 Feb;14(2):334–342. doi: 10.1200/JCO.1996.14.2.334. [DOI] [PubMed] [Google Scholar]
  26. Stahl M., Wilke H., Fink U., Stuschke M., Walz M. K., Siewert J. R., Molls M., Fett W., Makoski H. B., Breuer N. Combined preoperative chemotherapy and radiotherapy in patients with locally advanced esophageal cancer. Interim analysis of a phase II trial. J Clin Oncol. 1996 Mar;14(3):829–837. doi: 10.1200/JCO.1996.14.3.829. [DOI] [PubMed] [Google Scholar]
  27. Steeg P. S., Bevilacqua G., Kopper L., Thorgeirsson U. P., Talmadge J. E., Liotta L. A., Sobel M. E. Evidence for a novel gene associated with low tumor metastatic potential. J Natl Cancer Inst. 1988 Apr 6;80(3):200–204. doi: 10.1093/jnci/80.3.200. [DOI] [PubMed] [Google Scholar]
  28. Timmer-Bosscha H., Timmer A., Meijer C., de Vries E. G., de Jong B., Oosterhuis J. W., Mulder N. H. cis-diamminedichloroplatinum(ii) resistance in vitro and in vivo in human embryonal carcinoma cells. Cancer Res. 1993 Dec 1;53(23):5707–5713. [PubMed] [Google Scholar]
  29. Tokunaga Y., Urano T., Furukawa K., Kondo H., Kanematsu T., Shiku H. Reduced expression of nm23-H1, but not of nm23-H2, is concordant with the frequency of lymph-node metastasis of human breast cancer. Int J Cancer. 1993 Aug 19;55(1):66–71. doi: 10.1002/ijc.2910550113. [DOI] [PubMed] [Google Scholar]
  30. Yamamoto K., Oka M., Hayashi H., Tangoku A., Gondo T., Suzuki T. CYFRA 21-1 is a useful marker for esophageal squamous cell carcinoma. Cancer. 1997 May 1;79(9):1647–1655. [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES